Celldex Therapeutics (CLDX) 3.35 $CLDX
Celldex Appoints Elizabeth Crowley as Chief Product Development Officer
GlobeNewswire - Thu Aug 11, 7:01AM CDT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product Development Officer. Ms. Crowley was previously Senior Vice President of Product Development of Celldex and brings almost 25 years of industry experience where she was responsible for leading the execution of multiple successful drug development programs.
CLDX: 3.35 (-0.01)
Celldex (CLDX) Posts Narrower Q2 Loss, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:01AM CDT
While Celldex's (CLDX) Q2 loss was narrower-than-expected, focus remains primarily on the company's pipeline progress.
ANIP: 59.86 (-1.56), CLDX: 3.35 (-0.01), BMY: 56.35 (-0.41)
Celldex Reports Second Quarter 2016 Results
GlobeNewswire - Mon Aug 08, 3:01PM CDT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2016.
CLDX: 3.35 (-0.01)
Celldex (CLDX): What's Ahead for the Stock in Q2 Earnings?
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 8:07AM CDT
With no approved product in its portfolio, investors will remain focused on pipeline related updates from Celldex (CLDX).
CLDX: 3.35 (-0.01), INCY: 82.02 (+1.21), BMY: 56.35 (-0.41), IONS: 29.46 (-0.58)
Celldex to Report Second Quarter 2016 Financial Results and Host Corporate 2016 Objectives Update Call
GlobeNewswire - Tue Aug 02, 3:30PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2016 financial results on Monday, August 8, 2016 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2016 financial results and to provide an update on key research and development and business objectives for the remainder of 2016.
CLDX: 3.35 (-0.01)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 80.85 (-0.08), ACAD: 31.59 (-0.51), OPK: 9.33 (+0.04), CLDX: 3.35 (-0.01)
Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 59.86 (-1.56), CLDX: 3.35 (-0.01), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Celldex Therapeutics' CDXâ?'1401, CDXâ?'301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma
GlobeNewswire - Sat Jun 04, 1:02PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today results from a Phase 2 clinical study evaluating CDXâ?'1401 and CDXâ?'301 in patients with malignant melanoma, which was conducted by the Cancer Immunotherapy Trials Network (CITN) under a Cooperative Research and Development Agreement (CRADA) between Celldex and the Cancer Therapy Evaluation Program of the National Cancer Institute. CDXâ?'1401 is an NYâ?'ESOâ?'1-antibody fusion protein for immunotherapy, and CDXâ?'301 (recombinant human Flt3 ligand) is a potent hematopoietic cytokine that uniquely expands dendritic cells and hematopoietic stem cells. Results from the study were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in a poster titled "A Phase 2, Open-label, Multicenter, Randomized Study of CDXâ?'1401, a Dendritic Cell Targeting NYâ?'ESOâ?'1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with CDXâ?'301, a Recombinant Human Flt3 Ligand."
CLDX: 3.35 (-0.01)
Celldex Therapeutics Rises 4.47% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 23, 4:18PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $4.03 to a high of $4.50. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $4.12 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 3.35 (-0.01)
Celldex (CLDX) Posts Wider Q1 Loss, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Fri May 06, 7:16AM CDT
Although Celldex (CLDX) posted a wider-than-expected loss, investor focus primarily remains on the company's pipeline.
ANIP: 59.86 (-1.56), CLDX: 3.35 (-0.01), BMY: 56.35 (-0.41)
Celldex Reports First Quarter 2016 Results
GlobeNewswire - Thu May 05, 7:01AM CDT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2016.
CLDX: 3.35 (-0.01)
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 56.56 (+0.88), ECYT: 2.97 (+0.02), CLDX: 3.35 (-0.01), LGND: 106.19 (-0.85), AMGN: 169.77 (-0.36), IONS: 29.46 (-0.58), REGN: 388.64 (-4.76)
This One Drug Alone Makes Celldex Therapeutics, Inc. a Buy (Hint: It's not Rintega)
Cory Renauer, The Motley Fool - Motley Fool - Fri Apr 29, 12:16PM CDT
Image source: Celldex Therapeutics Over the past year, clinical-stage biotech Celldex Therapeutics has lost over 86% of its value. A phase 3 failure during a generally bearish period for your industry can do that to a company that spends over...
CLDX: 3.35 (-0.01)
Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer
GlobeNewswire - Wed Apr 27, 7:04AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC) of the lung, who have progressed on prior platinum-based chemotherapy. Glembatumumab vedotin is a fully human monoclonal antibody-drug conjugate (ADC) that targets gpNMB, a protein overexpressed by multiple tumor types, including SCC of the lung, where approximately 85 percent of patients overexpress the marker. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome. Celldex has entered into a collaborative relationship with PrECOG, LLC, which represents a research network established by the Eastern Cooperative Oncology Group (ECOG), and PrECOG, LLC will conduct the study.
CLDX: 3.35 (-0.01)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 4.94 (-0.05), CLDX: 3.35 (-0.01), XON: 25.33 (+0.04), MNKD: 0.74 (unch)
3 Charts That Explain Celldex Therapeutics Stock
Keith Speights, The Motley Fool - Motley Fool - Fri Apr 22, 8:41AM CDT
Image Source: Celldex Therapeutics Many considered it one of the most promising biotechs around. Celldex Therapeutics appeared to be on the cusp of a major breakthrough in brain cancer immunotherapy, with its market cap reflecting high...
CLDX: 3.35 (-0.01), BMY: 56.35 (-0.41)
Get The Jump On Next Week With These 4 Trending Small Cap Stocks
ACCESSWIRE - Fri Apr 22, 8:19AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. CBYL, UNXL, CLDX and BCEI are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
UNXL: 1.48 (unch), CLDX: 3.35 (-0.01), BCEI: 1.04 (+0.01), CBYL: 0.49 (+0.01)
Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. The Company previously reported on four poster presentations at AACR, which included Phase 1 safety and immune response data from the ongoing study evaluating varlilumab and nivolumab in patients with advanced cancers. New presentations included data enhancing the understanding of glembatumumab vedotin's mechanism of action and further validation of the overexpression of its target, gpNMB, in a wide range of tumor types. Additionally, the Company also presented research with lead agonist antibodies targeting the CD40 receptor, a promising target for immunotherapy, in a poster titled "Development and characterization of novel CD40 antibody agonists for cancer immunotherapy."
CLDX: 3.35 (-0.01)
Celldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016
GlobeNewswire - Mon Apr 18, 8:00AM CDT
-- All varlilumab dose levels showed acceptable tolerability/safety in combination regimen; Phase 2 portion of study now open to enrollment --
CLDX: 3.35 (-0.01)
Celldex Appoints Elizabeth Crowley as Chief Product Development Officer
GlobeNewswire - Thu Aug 11, 7:01AM CDT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product Development Officer. Ms. Crowley was previously Senior Vice President of Product Development of Celldex and brings almost 25 years of industry experience where she was responsible for leading the execution of multiple successful drug development programs.
CLDX: 3.35 (-0.01)
Celldex (CLDX) Posts Narrower Q2 Loss, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:01AM CDT
While Celldex's (CLDX) Q2 loss was narrower-than-expected, focus remains primarily on the company's pipeline progress.
ANIP: 59.86 (-1.56), CLDX: 3.35 (-0.01), BMY: 56.35 (-0.41)
Celldex Reports Second Quarter 2016 Results
GlobeNewswire - Mon Aug 08, 3:01PM CDT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2016.
CLDX: 3.35 (-0.01)
Celldex (CLDX): What's Ahead for the Stock in Q2 Earnings?
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 8:07AM CDT
With no approved product in its portfolio, investors will remain focused on pipeline related updates from Celldex (CLDX).
CLDX: 3.35 (-0.01), INCY: 82.02 (+1.21), BMY: 56.35 (-0.41), IONS: 29.46 (-0.58)
Celldex to Report Second Quarter 2016 Financial Results and Host Corporate 2016 Objectives Update Call
GlobeNewswire - Tue Aug 02, 3:30PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2016 financial results on Monday, August 8, 2016 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2016 financial results and to provide an update on key research and development and business objectives for the remainder of 2016.
CLDX: 3.35 (-0.01)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 80.85 (-0.08), ACAD: 31.59 (-0.51), OPK: 9.33 (+0.04), CLDX: 3.35 (-0.01)
Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 59.86 (-1.56), CLDX: 3.35 (-0.01), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Celldex Therapeutics' CDXâ?'1401, CDXâ?'301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma
GlobeNewswire - Sat Jun 04, 1:02PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today results from a Phase 2 clinical study evaluating CDXâ?'1401 and CDXâ?'301 in patients with malignant melanoma, which was conducted by the Cancer Immunotherapy Trials Network (CITN) under a Cooperative Research and Development Agreement (CRADA) between Celldex and the Cancer Therapy Evaluation Program of the National Cancer Institute. CDXâ?'1401 is an NYâ?'ESOâ?'1-antibody fusion protein for immunotherapy, and CDXâ?'301 (recombinant human Flt3 ligand) is a potent hematopoietic cytokine that uniquely expands dendritic cells and hematopoietic stem cells. Results from the study were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in a poster titled "A Phase 2, Open-label, Multicenter, Randomized Study of CDXâ?'1401, a Dendritic Cell Targeting NYâ?'ESOâ?'1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with CDXâ?'301, a Recombinant Human Flt3 Ligand."
CLDX: 3.35 (-0.01)
Celldex Therapeutics Rises 4.47% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 23, 4:18PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $4.03 to a high of $4.50. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $4.12 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 3.35 (-0.01)
Celldex (CLDX) Posts Wider Q1 Loss, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Fri May 06, 7:16AM CDT
Although Celldex (CLDX) posted a wider-than-expected loss, investor focus primarily remains on the company's pipeline.
ANIP: 59.86 (-1.56), CLDX: 3.35 (-0.01), BMY: 56.35 (-0.41)
Celldex Reports First Quarter 2016 Results
GlobeNewswire - Thu May 05, 7:01AM CDT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2016.
CLDX: 3.35 (-0.01)
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 56.56 (+0.88), ECYT: 2.97 (+0.02), CLDX: 3.35 (-0.01), LGND: 106.19 (-0.85), AMGN: 169.77 (-0.36), IONS: 29.46 (-0.58), REGN: 388.64 (-4.76)
This One Drug Alone Makes Celldex Therapeutics, Inc. a Buy (Hint: It's not Rintega)
Cory Renauer, The Motley Fool - Motley Fool - Fri Apr 29, 12:16PM CDT
Image source: Celldex Therapeutics Over the past year, clinical-stage biotech Celldex Therapeutics has lost over 86% of its value. A phase 3 failure during a generally bearish period for your industry can do that to a company that spends over...
CLDX: 3.35 (-0.01)
Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer
GlobeNewswire - Wed Apr 27, 7:04AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC) of the lung, who have progressed on prior platinum-based chemotherapy. Glembatumumab vedotin is a fully human monoclonal antibody-drug conjugate (ADC) that targets gpNMB, a protein overexpressed by multiple tumor types, including SCC of the lung, where approximately 85 percent of patients overexpress the marker. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome. Celldex has entered into a collaborative relationship with PrECOG, LLC, which represents a research network established by the Eastern Cooperative Oncology Group (ECOG), and PrECOG, LLC will conduct the study.
CLDX: 3.35 (-0.01)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 4.94 (-0.05), CLDX: 3.35 (-0.01), XON: 25.33 (+0.04), MNKD: 0.74 (unch)
3 Charts That Explain Celldex Therapeutics Stock
Keith Speights, The Motley Fool - Motley Fool - Fri Apr 22, 8:41AM CDT
Image Source: Celldex Therapeutics Many considered it one of the most promising biotechs around. Celldex Therapeutics appeared to be on the cusp of a major breakthrough in brain cancer immunotherapy, with its market cap reflecting high...
CLDX: 3.35 (-0.01), BMY: 56.35 (-0.41)
Get The Jump On Next Week With These 4 Trending Small Cap Stocks
ACCESSWIRE - Fri Apr 22, 8:19AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. CBYL, UNXL, CLDX and BCEI are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
UNXL: 1.48 (unch), CLDX: 3.35 (-0.01), BCEI: 1.04 (+0.01), CBYL: 0.49 (+0.01)
Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. The Company previously reported on four poster presentations at AACR, which included Phase 1 safety and immune response data from the ongoing study evaluating varlilumab and nivolumab in patients with advanced cancers. New presentations included data enhancing the understanding of glembatumumab vedotin's mechanism of action and further validation of the overexpression of its target, gpNMB, in a wide range of tumor types. Additionally, the Company also presented research with lead agonist antibodies targeting the CD40 receptor, a promising target for immunotherapy, in a poster titled "Development and characterization of novel CD40 antibody agonists for cancer immunotherapy."
CLDX: 3.35 (-0.01)
Celldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016
GlobeNewswire - Mon Apr 18, 8:00AM CDT
-- All varlilumab dose levels showed acceptable tolerability/safety in combination regimen; Phase 2 portion of study now open to enrollment --
CLDX: 3.35 (-0.01)
